Paxlovid (CAS 2628280-40-8)
🌟 ChemicalBook Product Introduction
📌 Product Overview
Paxlovid is an FDA-approved antiviral medication developed by Pfizer for treating mild-to-moderate COVID-19 in adults with high-risk factors, such as obesity, diabetes, or cardiovascular diseases. Its active ingredients, Nirmatrelvir (PF-07321332) and Ritonavir, work synergistically to inhibit the SARS-CoV-2 3CL protease, blocking viral replication. The compound is supplied as a white crystalline powder with a molecular formula of C23H32F3N5O4 and a purity of ≥99% (HPLC verified).
Google Keywords: Paxlovid CAS 2628280-40-8, Nirmatrelvir Supplier, COVID-19 Antiviral API, High-Purity Ritonavir
✅ Key Advantages
🔹 High Purity & Stability
≥99% purity (HPLC/UV verified) | Stable storage at 2-8°C.
🔹 Dual-Action Formula
Combines Nirmatrelvir (protease inhibitor) and Ritonavir (bioavailability enhancer) for enhanced efficacy.
🔹 Global Compliance
Produced in GMP-certified facilities | Meets EP/USP/CP standards.
🏥 Application Fields
COVID-19 Treatment: Primary use for high-risk adults within 5 days of symptom onset.
Clinical Research: Development of antiviral therapies and resistance studies.
Combination Therapies: Potential synergy with immunomodulators or other antivirals.
📜 Quality Certifications
Testing Methods: HPLC, NMR, MS, and microbial limit testing.
Certifications: ISO 9001, GMP, and FDA-aligned protocols.
📊 Market Trends
The global demand for COVID-19 therapeutics remains strong, particularly in Asia-Pacific regions, driven by emerging variants and post-pandemic preparedness. Paxlovid continues to be a critical tool in managing high-risk cases.
China
